This company listing is no longer active
EO7 Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Endo Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.01 |
| 52 Week High | €0.14 |
| 52 Week Low | €0.0002 |
| Beta | 0.80 |
| 11 Month Change | 400.00% |
| 3 Month Change | 0% |
| 1 Year Change | -88.89% |
| 33 Year Change | -99.79% |
| 5 Year Change | -99.86% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| EO7 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -1.8% |
| 1Y | -88.9% | -12.8% | 13.6% |
Return vs Industry: EO7 underperformed the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: EO7 underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| EO7 volatility | |
|---|---|
| EO7 Average Weekly Movement | 214.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EO7's share price has been volatile over the past 3 months.
Volatility Over Time: EO7's weekly volatility has increased from 144% to 214% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo Inc. Fundamentals Summary
| EO7 fundamental statistics | |
|---|---|
| Market cap | €141.13k |
| Earnings (TTM) | -€2.28b |
| Revenue (TTM) | €1.87b |
0.0x
P/S Ratio0.0x
P/E RatioIs EO7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EO7 income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$941.90m |
| Gross Profit | US$1.07b |
| Other Expenses | US$3.52b |
| Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.41 |
| Gross Margin | 53.17% |
| Net Profit Margin | -121.69% |
| Debt/Equity Ratio | -123.5% |
How did EO7 perform over the long term?
See historical performance and comparison